Business Wire

ISACA

18.1.2024 13:01:32 CET | Business Wire | Press release

Share
Privacy Budgets Expected to Decrease in 2024, New Research From ISACA Reveals

Two in every five (41%) privacy professionals in Europe state their budgets are underfunded and over half (56%) expect them to decrease this year. That’s according to new research from ISACA, the leading global professional association helping individuals and organisations in their pursuit of digital trust.

Anticipated drops in privacy budgets come despite half (53%) of organisations reporting that their technical privacy teams are understaffed. Two in five (41%) businesses also state that they have trouble retaining qualified privacy professionals.

Reducing Privacy budgets would be deemed normal if privacy operations where considered mature and mainstream vs the initial years of investment. This however is not the case based on the report, while the combination of reduced investments with lack of skills in an increasingly sophisticated cyberthreat landscape is the recipe for disaster. It is also proof that more holistic training at a board and privacy leader level needs to take place for both understanding and communicating the needs respectively.” says Chris Dimitriadis, Global Chief Strategy Officer at ISACA.

To combat some of the challenges they’re facing, organisations have been diligent about providing training to employees – 68% of privacy professionals say their company offers privacy training annually while 58% offer training when new hires are made. 71% of respondents say privacy training and awareness programs have had a positive impact on wider employee privacy awareness.

However, there is still a long way to go for businesses, as only 10% of respondents feel completely confident in their organisation's privacy team's ability to ensure data privacy and achieve compliance with new privacy laws and regulations.

It’s clear that a skills gap still prevails for core privacy staff. Experience with different types of technologies or applications (65%), technical expertise (50%) and IT operations knowledge (42%) are the biggest skills gaps privacy professionals are facing within their teams.

Reassuringly, organisations are taking steps to reduce that skills gap, with 52% offering training to allow non-privacy staff to move into privacy roles, while 39% are increasing the usage of contractors or external consultants.

“Organisations clearly crave expertise when it comes to managing privacy compliance and issues. This starts with putting the right resources towards privacy training and prioritisation. Only then can they protect their data, build trust with consumers, and preserve supplier relationships. Better privacy ultimately benefits us all,” adds Safia Kazi, ISACA principal, privacy professional practices.

For more information, read ISACA’s Privacy in Practice 2024 report here.

Notes to Editors

All figures are based on fieldwork conducted by ISACA between 13 and 31 October 2023 amongst a total of 305 privacy professionals in Europe. In total, ISACA surveyed more than 1,300 privacy professionals worldwide.

About ISACA

ISACA® (www.isaca.org) is a global community advancing individuals and organizations in their pursuit of digital trust. For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organizations, and build a more trusted and ethical digital world. ISACA is a global professional association and learning organization that leverages the expertise of its 170,000 members who work in digital trust fields such as information security, governance, assurance, risk, privacy and quality. It has a presence in 188 countries, including 225 chapters worldwide. ISACA's member base in Europe exceeds 30,000, and the organization has further strengthened its presence in the region by establishing a regional office in Dublin, Ireland, in 2022. Through its foundation One In Tech, ISACA supports IT education and career pathways for underresourced and underrepresented populations.

Twitter: www.twitter.com/ISACANews
LinkedIn: www.linkedin.com/company/isaca
Facebook: www.facebook.com/ISACAGlobal
Instagram: www.instagram.com/isacanews

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240118238720/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye